Market closedNon-fractionalADR
Adagene/ADAG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Adagene
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Ticker
ADAG
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Suzhou, China
Employees
174
Website
www.adagene.com
Adagene Metrics
BasicAdvanced
$124M
Market cap
-
P/E ratio
-$0.43
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$124M
52-week high
$4.38
52-week low
$1.10
Average daily volume
0.72
Financial strength
Current ratio
3.606
Long term debt to equity
19.19
Total debt to equity
31.09
Management effectiveness
Return on assets (TTM)
-14.13%
Return on equity (TTM)
-24.66%
Return on investment (TTM)
-20.87%
Valuation
Price to revenue (TTM)
6.827
Price to book
1.751
Price to tangible book (TTM)
1.752
Growth
Revenue change (TTM)
94.90%
Earnings per share change (TTM)
76.57%
3-year revenue growth (CAGR)
195.64%
What the Analysts think about Adagene
Analyst Ratings
Majority rating from 2 analysts.
Adagene Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$800K
-95.35%
Net income
-$15M
260.98%
Profit margin
-1,850.00%
7,663.32%
Adagene Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Actual
-$0.87
-
Expected
-$0.93
-$0.42
Surprise
-6.45%
-
Adagene News
AllArticlesVideos
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
GlobeNewsWire·2 weeks ago
Adagene to Present at Investor Conferences in June
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adagene stock?
Adagene (ADAG) has a market cap of $124M as of July 27, 2024.
What is the P/E ratio for Adagene stock?
The price to earnings (P/E) ratio for Adagene (ADAG) stock is 0 as of July 27, 2024.
Does Adagene stock pay dividends?
No, Adagene (ADAG) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Adagene dividend payment date?
Adagene (ADAG) stock does not pay dividends to its shareholders.
What is the beta indicator for Adagene?
Adagene (ADAG) does not currently have a Beta indicator.
Buy or sell Adagene stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.